High analytical concordance between a novel companion diagnostic assay and an IUO assay for BRAF V600E/V600K detection in melanoma

被引：0
|
作者：
O'Donnell, L. [1 ]
Sweet, W. [1 ]
Lu, X. [1 ]
Meynier, F. [2 ]
Derome, A. [3 ]
Ganee, L. [4 ]
Poyet-Gelas, F. [3 ]
Martin, A. [5 ]
Casey, M. [6 ]
Kertesz, N. [7 ]
机构：
[1] BioMerieux Inc, Clin Affairs, Durham, NC USA
[2] BioMerieux Inc, BioMath, Grenoble, France
[3] BioMerieux Inc, V&V, Grenoble, France
[4] BioMerieux Inc, Prod Design & Dev, Grenoble, France
[5] GSK, Oncol, Collegeville, PA USA
[6] GSK, Stat, Collegeville, PA USA
[7] Response Genet Inc, Pharmaceut Liaison Manager, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MC13-0053
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [11] Characteristics of BRAF V600K versus V600E: Effect of molecular weight change in melanoma
    Joob, Beuy
    Wiwanitkit, Viroj
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (01) : 291 - 291
  • [12] Trametinib plus dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (07): : 234 - 235
  • [13] Clinicopathologic Features of V600E and V600K Melanoma-Letter
    Jewell, Rosalyn
    Chambers, Philip
    Harland, Mark
    Laye, Jon
    Conway, Caroline
    Mitra, Angana
    Elliott, Faye
    Cook, Martin G.
    Boon, Andy
    Newton-Bishop, Julia
    CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6792 - 6792
  • [14] Clinicopathologic Features of V600E and V600K Melanoma-Response
    Menzies, Alexander M.
    Long, Georgina V.
    CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6793 - 6793
  • [15] Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
    Menzies, Alexander M.
    Haydu, Lauren E.
    Visintin, Lydia
    Carlino, Matteo S.
    Howle, Julie R.
    Thompson, John F.
    Kefford, Richard F.
    Scolyer, Richard A.
    Long, Georgina V.
    CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3242 - 3249
  • [16] A HRM assay for identification of low level BRAF V600E and V600K mutations using the CADMA principle in FFPE specimens
    Huebner, Claudia
    Weber, Remeny
    Lloydd, Richard
    PATHOLOGY, 2017, 49 (07) : 776 - 783
  • [17] Validation of a BRAF V600E/K/R ddPCR Assay
    Maniaci, J.
    Hoerres, D.
    Weck, K.
    Booker, J.
    Merker, J.
    Phillips, K.
    Galeotti, J.
    Gulley, M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (11): : S18 - S19
  • [18] Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma
    da Silva, Ines Pires
    Wang, Kevin Y. X.
    Wilmott, James S.
    Holst, Jeff
    Carlino, Matteo S.
    Park, John J.
    Quek, Camelia
    Wongchenko, Matthew
    Yan, Yibing
    Mann, Graham
    Johnson, Douglas B.
    McQuade, Jennifer L.
    Rai, Rajat
    Kefford, Richard F.
    Rizos, Helen
    Scolyer, Richard A.
    Yang, Jean Y. H.
    Long, Georgina V.
    Menzies, Alexander M.
    CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1272 - 1279
  • [19] Detection of BRAF V600K Mutations in Melanoma: A Comparison of Cobas 4800 BRAF V600 Mutation Test and Laboratory Developed Pyrosequencing Assay
    Wenceslao, S. M.
    Gale, J.
    Vasef, M. A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2012, 14 (06): : 700 - 701
  • [20] The BRAF V600K Mutation Is More Frequent than the BRAF V600E Mutation in Melanoma In Situ of Lentigo Maligna Type
    Stadehneyer, Eike
    Heitzer, Ellen
    Resel, Margit
    Cerroni, Lorenzo
    Wolf, Peter
    Dandachi, Nadia
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (02) : 548 - 550
12345